trifonazole
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started Oct 1, 2008 (NCT00781820)
Timeline
Indications
Approved for
Mechanism of action
- ErgosterolINHIBITOR
Ergosterol inhibitor
- HMG-CoA reductaseINHIBITOR
HMG-CoA reductase inhibitor
In dermatophytes, HMG-CoA reductase is also inhibited.
- Lanosterol 14-alpha demethylaseINHIBITOR
Lanosterol 14-alpha demethylase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1- Mol. weight
- 310.4 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL277535 ↗
Also known as
- (+-)1-([1,1'-biphenyl]-4-ylphenylmethyl)-1h-imidazole
- (+-)1-([1,1'-biphenyl]-4-ylphenylmethyl)-1h-imidazole
- 1-((4-biphenylyl)phenylmethyl)-1h-imidazole
- 1-((4-biphenylyl)phenylmethyl)-1h-imidazole
- 1-(alpha-(4-biphenylyl)benzyl)imidazole
- 1-(alpha-(4-biphenylyl)benzyl)imidazole
- (+-)-1-(p,alpha-diphenylbenzyl)imidazole
- (+-)-1-(p,alpha-diphenylbenzyl)imidazole
- 1-(p,alpha-diphenylbenzyl)imidazole
- 1-(p,alpha-diphenylbenzyl)imidazole
- amycor
- bay h 4502
- bay h 4502
- bay h 4502
- bay h-4502
- bay-h-4502
- bay-h-4502
- bifazol
- bifokey
- bifomyk
- bifon
- bifonazol
- bifonazol
- bifonazole
- bifonazole
- bifonazole
- bifonazole
- bifonazole
- bifonazole
- bifonazole
- bifonazole
- (+/-)-bifonazole
- bifonazolum
- bifonazolum
- canesten brand of bifonazole
- moldina
- mycospor
- mycospor
- mycospor
- mycospor
- trifonazole
- trifonazole
- trifonazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02705664 | Phase 4 | Jan 1, 2016 | Cutis Ehf, Galderma |
| NCT01013909 | Phase 2 | Dec 1, 2009 | Bayer |
| NCT00781820 | Phase 3 | Oct 1, 2008 | Bayer |
Showing 3 of 3 trials
Page 1 / 1